Funding Round attributes
Tethis, a Milan-based cancer diagnostics company, has announced the successful closure of a €15 million funding round. The investment was led by Enea TECH and Biomedical Foundation, marking a significant step forward for the company in its mission to advance liquid biopsy technologies.
The funding will be used to accelerate the development, validation, and preparation for the commercialization of Tethis’s diagnostic platform. This platform is designed to provide a non-invasive method for cancer detection through liquid biopsy—a blood test capable of identifying traces of tumor cells circulating in the bloodstream. The company’s technology is particularly focused on offering a less invasive alternative to traditional diagnostic procedures while maintaining precision and reliability.
Under the leadership of CEO Holger Neecke, Tethis has developed an integrated analytical process that forms the foundation of its liquid biopsy solutions. Central to this process is the See.d® blood sample preparation instrument, which is designed to optimize the analysis of blood samples. The platform also incorporates SmartBioSurface® slides, which are treated with biocompatible nanomaterials to enhance the capture and identification of cellular elements associated with tumors. Additionally, artificial intelligence algorithms play a critical role in identifying cellular components of tumor origin, providing an advanced layer of analytical capability.
This funding round builds on previous investments from Genextra and Indaco Venture Partners, highlighting ongoing confidence in Tethis’s innovative approach to cancer diagnostics. The company’s focus on integrating advanced materials, precise analytical tools, and AI-driven processes into its platform positions it as a key player in the emerging field of liquid biopsy technology.
The investment from Enea TECH and Biomedical Foundation underscores the growing interest in technologies that have the potential to revolutionize cancer diagnostics. Liquid biopsy is increasingly being recognized for its potential to detect cancer earlier and with greater convenience compared to traditional methods. By leveraging this funding, Tethis aims to move closer to bringing its diagnostic platform to the market, enabling broader access to its innovative solutions.
Tethis’s approach to liquid biopsy emphasizes not only technical precision but also scalability and adaptability, making it suitable for various clinical and research applications. The integration of nanomaterials and AI algorithms enhances the platform’s ability to provide detailed insights into tumor biology, contributing to its value in personalized medicine and cancer treatment planning.
As the company advances its research and commercialization efforts, the new funding will support critical steps, including further validation studies and regulatory preparations. These efforts are aimed at ensuring the platform meets the stringent requirements of clinical use while maintaining high standards of accuracy and reliability.
In summary, Tethis’s €15 million funding round represents a significant milestone in its journey to transform cancer diagnostics. With the support of Enea TECH and Biomedical Foundation, as well as prior investors, the company is poised to continue its work on developing a cutting-edge diagnostic platform that has the potential to make a meaningful impact on cancer detection and patient outcomes.
